Foghorn Therapeutics (FHTX) Cash from Operations (2019 - 2026)

Foghorn Therapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 25266000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 5.42% year-over-year to 25266000.0; the TTM figure through Mar 2026 stood at 87397000.0 (up 8.03% YoY), while the FY2025 annual figure was 86099000.0, up 14.25% from the prior year.
• Cash from Operations was 25266000.0 for Q1 2026 at Foghorn Therapeutics, down from 22271000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 271534000.0 in Q1 2022 to a low of 32175000.0 in Q2 2023.
• Historically, Cash from Operations has averaged 8015588.24 across 5 years, with a median of 25266000.0 in 2026.
• Biggest YoY gain for Cash from Operations was 1273.09% in 2022; the steepest drop was 343.43% in 2022.
• A 5-year view of Cash from Operations shows it stood at 28924000.0 in 2022, then advanced by 4.78% to 27541000.0 in 2023, then rose by 10.97% to 24519000.0 in 2024, then gained by 9.17% to 22271000.0 in 2025, then dropped by 13.45% to 25266000.0 in 2026.
• The last three Cash from Operations figures came in at 25266000.0 (Q1 2026), 22271000.0 (Q4 2025), and 18860000.0 (Q3 2025), per Business Quant data.